Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 4 (April)

1. Critical analysis of reduction mammaplasty techniques in combination with conservative breast surgery for early breast cancer treatment.
   Plast Reconstr Surg, 117(4): 1091-103; discussion 1104-7. [Abstract] [Full-text]
2. Breast reconstruction following subcutaneous mastectomy for cancer: a critical appraisal of the nipple-areola complex.
   Plast Reconstr Surg, 117(4): 1083-90. [Abstract] [Full-text]
3. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.
   Int J Radiat Oncol Biol Phys, 64(5): 1401-9. [Abstract] [Full-text]
4. Intraoperative radiotherapy given as a boost for early breast cancer: long-term clinical and cosmetic results.
   Int J Radiat Oncol Biol Phys, 64(5): 1410-5. [Abstract] [Full-text]
5. Vitamin D3 suppresses the androgen-stimulated growth of mouse mammary carcinoma SC-3 cells by transcriptional repression of fibroblast growth factor 8.
   J Cell Physiol, 207(3): 793-9. [Abstract] [Full-text]
6. STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma.
   Int J Cancer, 118(12): 2943-7. [Abstract] [Full-text]
7. A history of cancer in the husband does not increase the risk of breast cancer.
   Int J Cancer, 118(12): 3177-9. [Abstract] [Full-text]
8. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens.
   Int J Cancer, 118(12): 3112-7. [Abstract] [Full-text]
9. Loss of RAB25 expression in breast cancer.
   Int J Cancer, 118(12): 2957-64. [Abstract] [Full-text]
10. Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast.
    Toxicol Lett, 163(3): 224-34. [Abstract] [Full-text]
11. Meta-analysis of soy intake and breast cancer risk.
    J Natl Cancer Inst, 98(7): 459-71. [Abstract] [Full-text]
12. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients.
    Br J Cancer, 94(7): 1057-65. [Abstract] [Full-text]
13. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
    Br J Cancer, 94(7): 1016-20. [Abstract] [Full-text]
14. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome.
    Br J Cancer, 94(7): 1066-70. [Abstract] [Full-text]
15. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole.
    Br J Cancer, 94(7): 1051-6. [Abstract] [Full-text]
16. Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations.
    Br J Cancer, 94(7): 1021-8. [Abstract] [Full-text]
17. Use of antidepressant medications in relation to the incidence of breast cancer.
    Br J Cancer, 94(7): 1071-8. [Abstract] [Full-text]
18. Mortality from all cancers and lung, colorectal, breast and prostate cancer by country of birth in England and Wales, 2001-2003.
    Br J Cancer, 94(7): 1079-85. [Abstract] [Full-text]
19. Mapping and conformational characterization of the DNA-binding region of the breast cancer susceptibility protein BRCA1.
    Biochem J, 395(3): 529-35. [Abstract] [Full-text]
20. An osteopontin splice variant induces anchorage independence in human breast cancer cells.
    Oncogene, 25(15): 2192-202. [Abstract] [Full-text]
21. Gene expression profiling of breast cell lines identifies potential new basal markers.
    Oncogene, 25(15): 2273-84. [Abstract] [Full-text]
22. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
    Am J Clin Oncol, 29(2): 171-7. [Abstract] [Full-text]
23. A common polymorphism renders the luteinizing hormone receptor protein more active by improving signal peptide function and predicts adverse outcome in breast cancer patients.
    J Clin Endocrinol Metab, 91(4): 1470-6. [Abstract] [Full-text]
24. Association of prolactin and its receptor gene regions with familial breast cancer.
    J Clin Endocrinol Metab, 91(4): 1513-9. [Abstract] [Full-text]
25. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
    BMC Cancer, 6: 76. [Abstract] [Full-text]
26. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
    J Clin Oncol, 24(11): 1656-64. [Abstract] [Full-text]
27. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
    J Clin Oncol, 24(11): 1665-71. [Abstract] [Full-text]
28. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
    JAMA, 295(14): 1658-67. [Abstract] [Full-text]
29. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.
    JAMA, 295(14): 1647-57. [Abstract] [Full-text]
30. Breast cancer in octogenarians.
    Cancer, 106(8): 1664-8. [Abstract] [Full-text]
31. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation.
    Oncogene, 25(16): 2379-92. [Abstract] [Full-text]
32. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics.
    Oncogene, 25(16): 2328-38. [Abstract] [Full-text]
33. A risk index for early node-negative breast cancer.
    Br J Surg, 93(5): 564-71. [Abstract] [Full-text]
34. Intraoperative touch imprint cytology for the diagnosis of sentinel lymph node metastases in breast cancer.
    Br J Surg, 93(5): 572-6. [Abstract] [Full-text]
35. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.
    Br J Surg, 93(5): 539-46. [Abstract] [Full-text]
36. Evaluation of two tomotherapy-based techniques for the delivery of whole-breast intensity-modulated radiation therapy.
    Int J Radiat Oncol Biol Phys, 65(1): 284-90. [Abstract] [Full-text]
37. The impact of the number of excised axillary nodes and of the percentage of involved nodes on regional nodal failure in patients treated by breast-conserving surgery with or without regional irradiation.
    Int J Radiat Oncol Biol Phys, 65(1): 33-9. [Abstract] [Full-text]
38. Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: toxicity analysis of RTOG 95-17.
    Int J Radiat Oncol Biol Phys, 65(1): 45-51. [Abstract] [Full-text]
39. Factors associated with involvement of four or more axillary nodes for sentinel lymph node-positive patients.
    Int J Radiat Oncol Biol Phys, 65(1): 40-4. [Abstract] [Full-text]
40. Body radiation exposure in breast cancer radiotherapy: impact of breast IMRT and virtual wedge compensation techniques.
    Int J Radiat Oncol Biol Phys, 65(1): 52-8. [Abstract] [Full-text]
41. Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases.
    Int J Radiat Oncol Biol Phys, 65(1): 25-32. [Abstract] [Full-text]
42. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
    J Clin Oncol, 24(12): 1940-9. [Abstract] [Full-text]
43. Factors associated with participation in breast cancer treatment clinical trials.
    J Clin Oncol, 24(12): 1860-7. [Abstract] [Full-text]
44. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
    J Clin Oncol, 24(12): 1839-45. [Abstract] [Full-text]
45. Long-term cancer risk among Swedish women with cosmetic breast implants: an update of a nationwide study.
    J Natl Cancer Inst, 98(8): 557-60. [Abstract] [Full-text]
46. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).
    J Natl Cancer Inst, 98(8): 535-44. [Abstract] [Full-text]
47. Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement--Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer.
    J Clin Oncol, 24(12): 1814-22. [Abstract] [Full-text]
48. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk?
    J Clin Oncol, 24(12): 1823-30. [Abstract] [Full-text]
49. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
    J Clin Oncol, 24(12): 1831-8. [Abstract] [Full-text]
50. The changes of estrogen receptor-beta variants expression in breast carcinogenesis: Decrease of estrogen receptor-beta2 expression is the key event in breast cancer development.
    J Surg Oncol, 93(6): 504-10. [Abstract] [Full-text]
51. A pilot, prospective evaluation of a novel alternative for maintenance therapy of breast cancer-associated lymphedema [ISRCTN76522412].
    BMC Cancer, 6: 84. [Abstract] [Full-text]
52. Accuracy and self correction of information received from an internet breast cancer list: content analysis.
    BMJ, 332(7547): 939-42. [Abstract] [Full-text]
53. Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells.
    Exp Cell Res, 312(8): 1240-53. [Abstract] [Full-text]
54. Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells.
    Cancer Chemother Pharmacol, 58(1): 62-72. [Abstract] [Full-text]
55. Human breast cell lines exhibit functional alpha2-adrenoceptors.
    Cancer Chemother Pharmacol, 58(1): 50-61. [Abstract] [Full-text]
56. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.
    Cancer Chemother Pharmacol, 58(1): 129-35. [Abstract] [Full-text]
57. Estrogenic effect of procymidone through activation of MAPK in MCF-7 breast carcinoma cell line.
    Life Sci, 78(23): 2716-23. [Abstract] [Full-text]
58. Is there more to BARD1 than BRCA1?
    Nat Rev Cancer, 6(5): 382-91. [Abstract] [Full-text]
59. The use of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to detect putative breast cancer markers in saliva: a feasibility study.
    J Oral Pathol Med, 35(5): 292-300. [Abstract] [Full-text]
60. Fish consumption and breast cancer risk. The European Prospective Investigation into Cancer and Nutrition (EPIC).
    Int J Cancer, 119(1): 175-82. [Abstract] [Full-text]
61. Metabolic syndrome as a prognostic factor for breast cancer recurrences.
    Int J Cancer, 119(1): 236-8. [Abstract] [Full-text]
62. Performance of clinical mammography: a nationwide study from Denmark.
    Int J Cancer, 119(1): 183-91. [Abstract] [Full-text]
63. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors.
    Int J Cancer, 119(1): 108-16. [Abstract] [Full-text]
64. Nuclear targeting of a midregion PTHrP fragment is necessary for stimulating growth in breast cancer cells.
    Int J Cancer, 119(1): 49-59. [Abstract] [Full-text]
65. CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women.
    Toxicol Lett, 164(1): 90-5. [Abstract] [Full-text]
66. Effects of natural prenylated flavones in the phenotypical ER (+) MCF-7 and ER (-) MDA-MB-231 human breast cancer cells.
    Toxicol Lett, 164(1): 24-36. [Abstract] [Full-text]
67. Exposure to modeled microgravity induces metabolic idleness in malignant human MCF-7 and normal murine VSMC cells.
    FEBS Lett, 580(10): 2465-70. [Abstract] [Full-text]
68. The biochemical alterations following administration of Kalpaamruthaa and Semecarpus anacardium in mammary carcinoma.
    Chem Biol Interact, 161(1): 69-78. [Abstract] [Full-text]
69. The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin.
    Biochem Biophys Res Commun, 343(4): 1053-9. [Abstract] [Full-text]
70. Breast cancer incidence after the introduction of mammography screening: what should be expected?
    Cancer, 106(9): 1883-90. [Abstract] [Full-text]
71. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data.
    Cancer, 106(9): 1875-82. [Abstract] [Full-text]
72. Effects of weight training on quality of life in recent breast cancer survivors: the Weight Training for Breast Cancer Survivors (WTBS) study.
    Cancer, 106(9): 2076-83. [Abstract] [Full-text]
73. Evaluation of late results in breast reconstruction by latissimus dorsi flap and prosthesis implantation.
    Plast Reconstr Surg, 117(5): 1387-94. [Abstract] [Full-text]
74. Breast cancer local recurrence after mastectomy and TRAM flap reconstruction: incidence and treatment options.
    Plast Reconstr Surg, 117(5): 1381-6. [Abstract] [Full-text]
75. Breast cancer in the family--children's perceptions of their mother's cancer and its initial treatment: qualitative study.
    BMJ, 332(7548): 998-1003. [Abstract] [Full-text]
76. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
    Cancer Chemother Pharmacol, 58(2): 143-56. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.